Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The study will be investigating the effectiveness of oxycodone-naloxone (brand name Targin®)
at treating chronic pain in individuals with spinal cord injury. The goal of the study is to
compare the effectiveness of Targin® at treating chronic pain in individuals with sub-acute
and chronic spinal cord injury compared to opioid medication that is not compounded with
naloxone.
Phase:
Phase 4
Details
Lead Sponsor:
University of British Columbia
Collaborators:
International Collaboration On Repair Discoveries (ICORD) Purdue Pharma LP Purdue Pharma, Canada Vancouver Coastal Health